Cyclacel Pharmaceuticals to Present at 2007 BIO CEO & Investor Conference.BERKELEY HEIGHTS, N.J. -- First graph, second sentence should read: Mr. Rombotis' presentation will take place on Wednesday, February 14, 2007 at 12:45 pm EST EST electroshock therapy. EST abbr. electroshock therapy in the Basildon room at the Waldorf-Astoria Hotel in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , New York. (sted: ...Wednesday, February 14, 2007 at 2:15 pm EST in the East Foyer at the Waldorf-Astoria Hotel...) The corrected release reads: CYCLACEL PHARMACEUTICALS TO PRESENT AT 2007 BIO CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. & INVESTOR CONFERENCE Cyclacel Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CYCC CYCC Canadian Youth Climate Coalition , NASDAQ: CYCCP) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the 2007 BIO CEO & Investor Conference in New York. Mr. Rombotis' presentation will take place on Wednesday, February 14, 2007 at 12:45 pm EST in the Basildon room at the Waldorf-Astoria Hotel in New York, New York. The presentation will be webcast live at: www.corporate-ir.net/ireye/conflobby.zhtml?ticker=CYCC&item_id=14 The webcast will be available for one year. About Cyclacel Pharmaceuticals, Inc. Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The Company is currently evaluating seliciclib (CYC202), an orally-available cyclin cy·clin n. A class of proteins that fluctuate in concentration at specific points during the cell cycle and that regulate the cycle by binding to a kinase. dependent kinase inhibitor, in Phase IIb clinical trials for the treatment of lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. . Sapacitabine (CYC682), an orally-available, cell cycle modulating nucleoside nucleoside Any of a class of organic compounds, including structural subunits of nucleic acids. Each consists of a molecule of a five-carbon sugar (ribose in RNA, deoxyribose in DNA) and a nitrogen-containing base, either a purine or a pyrimidine. analog, is in Phase I clinical trials for the treatment of cancer. CYC116, an orally-available, Aurora kinase and VEGFR VEGFR Vascular Endothelial Growth Factor Receptor 2 inhibitor, is at the IND stage. Several additional programs are at an earlier stage. Note: The Cyclacel logo and Cyclacel[R] are trademarks of Cyclacel Pharmaceuticals, Inc. Risk Factors This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements Capital requirements Financing required for the operation of a business, composed of long-term and working capital plus fixed assets. , and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Forms S-3 (File No. 333-134945) and S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion